Research Update

 

TIDMNVOB 
 
RNS Number : 8104E 
Novo Nordisk A/S 
30 December 2009 
 

Company Announcement 
30 December 2009 
Update on timeline for formal feedback on liraglutide from the FDA 
Novo Nordisk today announced that formal feedback from the United States Food 
and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 
analogue, is expected within weeks. Novo Nordisk continues the constructive 
dialogue with the FDA regarding the regulatory process for liraglutide. 
Novo Nordisk expects to provide an update on the regulatory process 
for liraglutide in connection with the announcement of the financial results for 
2009 on 2 February 2010, if formal feedback is not received before then. 
About liraglutide 
Liraglutide is the first once-daily human Glucagon-Like Peptide-1 
(GLP-1) analogue developed for the treatment of type 2 diabetes. Liraglutide 
works by stimulating the release of insulin only when glucose levels become too 
high and by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New 
Drug Application to the Food and Drug Administration in the US for the approval 
of liraglutide for the treatment of people with type 2 diabetes. In Europe, Novo 
Nordisk received marketing authorisation for liraglutide under the brand name 
Victoza  on 30 June, and Victoza  has subsequently been launched. A New Drug 
Application was also submitted for approval in Japan on 14 July 2008. 
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. In 
addition, Novo Nordisk has a leading position within areas such as haemostasis 
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk 
manufactures and markets pharmaceutical products and services that make a 
significant difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 
countries, and markets its products in 179 countries. Novo Nordisk's B shares 
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed 
on the New York Stock Exchange under the symbol 'NVO'. For more information, 
visit novonordisk.com 
Further information: 
+------------------------------------+------------------------------------+ 
| Media:                             | Investors:                         | 
+------------------------------------+------------------------------------+ 
|                                    |                                    | 
+------------------------------------+------------------------------------+ 
| Mike Rulis                         | Mads Veggerby Lausten              | 
+------------------------------------+------------------------------------+ 
| Tel: [phone]               | Tel: [phone]               | 
+------------------------------------+------------------------------------+ 
| [e-mail]               | [e-mail]               | 
+------------------------------------+------------------------------------+ 
|                                    |                                    | 
+------------------------------------+------------------------------------+ 
|                                    | Kasper Roseeuw Poulsen             | 
+------------------------------------+------------------------------------+ 
|                                    | Tel: [phone]               | 
+------------------------------------+------------------------------------+ 
|                                    | [e-mail]               | 
+------------------------------------+------------------------------------+ 
|                                    |                                    | 
+------------------------------------+------------------------------------+ 
| In North America:                  | In North America:                  | 
+------------------------------------+------------------------------------+ 
| Sean Clements                      | Hans Rommer                        | 
+------------------------------------+------------------------------------+ 
| Tel: [phone]             | Tel: [phone]             | 
+------------------------------------+------------------------------------+ 
| [e-mail]               | [e-mail]               | 
+------------------------------------+------------------------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RESURVBRKNRUORA